Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Non Operating Income (2020 - 2023)

Cullinan Therapeutics has reported Non Operating Income over the past 4 years, most recently at -$117000.0 for Q4 2023.

  • Quarterly results put Non Operating Income at -$117000.0 for Q4 2023, down 139.26% from a year ago — trailing twelve months through Dec 2023 was $239000.0 (up 319.3% YoY), and the annual figure for FY2025 was -$443000.0, down 122.61%.
  • Non Operating Income for Q4 2023 was -$117000.0 at Cullinan Therapeutics, down from $180000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for CGEM hit a ceiling of $298000.0 in Q4 2022 and a floor of -$241000.0 in Q2 2022.
  • Median Non Operating Income over the past 4 years was -$500.0 (2020), compared with a mean of $23083.3.
  • Peak annual rise in Non Operating Income hit 7350.0% in 2022, while the deepest fall reached 2912.5% in 2022.
  • Cullinan Therapeutics' Non Operating Income stood at -$12000.0 in 2020, then surged by 133.33% to $4000.0 in 2021, then soared by 7350.0% to $298000.0 in 2022, then plummeted by 139.26% to -$117000.0 in 2023.
  • The last three reported values for Non Operating Income were -$117000.0 (Q4 2023), $180000.0 (Q3 2023), and $69000.0 (Q2 2023) per Business Quant data.